DNA cleavage inducer use to treat various cancers. It induces cell cycle arrest and apoptosis in hemangioma. It may inhibit thioredoxin reductase. (C003B-255802)

Catalog No.: C003B-255802
Mfr. No.: B4517-5 mg
Mfr. Name: LKT Laboratories, Inc
Qty/UOM: 1
UOM: EA

Price: $721.04

List Price: $801.16

Bleomycin A5 is an anticancer chemotherapeutic that binds DNA and induces DNA cleavage and strand breaks it is highly toxic. Bleomycin is clinically used to treat lymphomas, squamous cell carcinomas, and testicular cancer.

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

Bleomycin A5 is an anticancer chemotherapeutic that binds DNA and induces DNA cleavage and strand breaks; it is highly toxic. Bleomycin is clinically used to treat lymphomas, squamous cell carcinomas, and testicular cancer. Additionally, this compound induces apoptosis, alters cell cycle regulation, inhibits proliferation, and decreases tumor size in cellular and animal models of hemangioma. Bleomycin may also inhibit thioredoxin reductase.

UPC:: 51111733
Condition:: New
Availability:: 3 Days
Weight:: 1.00 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: B4517-5 mg
CAS:: 55658-47-4

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."